Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Triple Negative Breast Neoplasms × famitinib × Clear all

Phase

Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Non-squamous Non-small-cell Lung Cancer 1 Non Squamous Non Small Cell Lung 1 Gastrointestinal Stromal Tumors 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced NSCLC 1

Interventions

Paclitaxel 19 Carboplatin 18 Capecitabine 15 130-nm albumin-bound paclitaxel 14 Gemcitabine 13 pembrolizumab 11 Cyclophosphamide 9 atezolizumab 7 Epirubicin 7 sacituzumab govitecan 6 eribulin 6 Albumin-Bound Paclitaxel 6 Vinorelbine 5 Doxorubicin 5 Drug Therapy 4 camrelizumab 3 Docetaxel 3 Cisplatin 3 pegfilgrastim 2 Injections 2 Filgrastim 2 Everolimus 2 veliparib 1 trilaciclib 1 toripalimab 1 taxane 1 niraparib 1 ipatasertib 1 iniparib 1 famitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05999149 2024-02-21

BCTOP-T-N01

Fudan University

Phase 3 Recruiting

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡